By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


REGENX Biosciences, LLC 

750 17th St. NW, Suite 1100

Washington  D.C.   20006  U.S.A.
Phone: 202-785-7438 Fax:


Company News
REGENXBIO Files for $100 Milllion IPO 8/18/2015 7:46:19 AM
REGENXBIO Enters Into Strategic Manufacturing Collaboration With WuXi AppTec, Inc. 6/11/2015 7:25:21 AM
Dr. Jerry Karabelas Appointed To REGENXBIO Board Of Directors 5/27/2015 7:20:34 AM
REGENXBIO Banks $70.5 Million As Gene Therapy Enjoys Revival 5/20/2015 5:54:05 AM
REGENX Biosciences, LLC: Attacking A Rare Disease At Its Source With Gene Therapy 8/27/2014 6:48:27 AM
REGENX Biosciences, LLC And Voyager Pharmaceutical Corporation Announce License Agreement 6/2/2014 10:03:33 AM
REGENX Biosciences, LLC Enters Into License Agreement With AAVLife For Development Of Treatments For Friedreich's Ataxia Using NAV(R) Vectors 4/29/2014 11:15:18 AM
REGENX Biosciences, LLC And AveXis Enter Into Exclusive License Agreement For The Development Of Treatments For Spinal Muscular Atrophy Using NAV® rAAV9 Vectors 4/1/2014 11:09:56 AM
REGENX Biosciences, LLC And Esteve S.A. (Laboratorios Del Dr. Esteve S.A.) Enter Into License Agreement For Development Of Treatments For Serious, Rare Lysosomal Storage Disorder Using NAV® rAAV9 Vectors 3/10/2014 10:12:48 AM
Dr. James Brown, COO, REGENX Biosciences, LLC, Elected To SAFE-BioPharma, LLC Board Of Directors 2/11/2014 10:08:08 AM